



Nonclassical CD4 + CD49b + Regulatory T Cells as a Better Alternative to Conventional CD4 + CD25 + T Cells To Dampen Arthritis Severity

Rita Vicente, Julie Quentin, Anne-Laure Mausset-Bonnefont, Paul Chuchana, Delphine Martire, Mailys Cren, Christian Jorgensen, Pascale Louis-Plence

► To cite this version:

Rita Vicente, Julie Quentin, Anne-Laure Mausset-Bonnefont, Paul Chuchana, Delphine Martire, et al.. Nonclassical CD4 + CD49b + Regulatory T Cells as a Better Alternative to Conventional CD4 + CD25 + T Cells To Dampen Arthritis Severity. *Journal of Immunology*, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2015, 196 (1), pp.298 - 309. 10.4049/jimmunol.1501069 . hal-01834236

HAL Id: hal-01834236

<https://hal.umontpellier.fr/hal-01834236>

Submitted on 18 Dec 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Non-classical CD4⁺CD49b⁺ regulatory T cells as a better alternative to
conventional CD4⁺CD25⁺ T cells to dampen arthritis severity**

Rita Vicente^{1*†‡}, Julie Quentin^{1*†‡}, Anne-Laure Mausset-Bonnefont^{*†‡}, Paul
Chuchana^{*†‡}, Delphine Martire^{*†‡}, Maïlys Cren^{†‡}, Christian Jorgensen^{*†‡}, and
Pascale Louis-Plence^{*†‡}

* Inserm, U1183, Institute of Regenerative Medicine and Biotherapies, Montpellier,
France

† University of Montpellier, Montpellier, France.

‡ CHU Saint Eloi, Institute of Regenerative Medicine and Biotherapies, Montpellier,
France

¹ equally contributed to the study

Address correspondence to: Dr. Pascale Louis-Plence, Inserm U1183, IRMB, 80 rue
Augustin Fliche, 34295 Montpellier cedex 05, France.

Phone: (+33) 467 33 57 21/ Fax: (+33) 467 33 01 13

Email: pascale.plence@inserm.fr

Running title: CD49b⁺ Treg cells express multiple canonical Treg markers

25 Footnote:

26 This work was supported in part by research funding from the European Union
27 project Innovative Medicine Initiative 6 (“BeTheCure”; contract number 115142–2 to
28 C.J.) and by institutional fundings. J.Q. was supported by the Arthritis Foundation.

29

Abstract

Promising immunotherapeutic strategies are emerging to restore tolerance in autoimmune diseases by triggering an increase in the number and/or the function of endogenous regulatory T (Treg) cells, which actively control pathological immune responses. Evidence suggests a remarkable heterogeneity in peripheral Treg cells that warrants their better characterization in terms of phenotype and suppressive function, to determine which subset may be optimally suitable for a given clinical situation.

We found that repetitive injections of immature dendritic cells (DCs) expanded FoxP3-negative CD49b⁺ Treg cells that displayed an effector memory phenotype. These expanded Treg cells were isolated *ex-vivo* for transcriptome analysis and found to contain multiple transcripts of the canonical Treg signature shared mainly by CD25⁺ but also by other sub-phenotypes. We characterized the CD49b⁺ Treg cell phenotype, underscoring its similarities with the CD25⁺ Treg cell phenotype and highlighting some differential expression patterns for several markers, including LAG-3, KLRG1, CD103, ICOS, CTLA-4 and Granzyme B. Comparison of the CD25⁺ and CD49b⁺ Treg cells' suppressive mechanisms, *in vitro* and *in vivo*, revealed the latter's potent suppressive activity, which was partly dependent on IL-10 secretion. Altogether our results strongly suggest that expression of several canonical Treg cell markers and suppressive function could be FoxP3-independent, and underscore the therapeutic potential of IL-10 secreting CD49b⁺ Treg cells in arthritis.

Introduction

Regulatory T (Treg) cells actively suppress pathological and physiological immune responses, thereby contributing to the maintenance of immunological self-tolerance and immune homeostasis. Their development occurs in the thymus as a result of high-avidity TCR interactions with self-Ags (1), and are called thymus-derived Treg (tTreg) cells. These Treg cell subset are characterized by a stable expression of the transcription factor forkhead box P3 (FoxP3) (2) and constitutive high-level expression of CD25 (IL-2 receptor α chain) and thus denoted as CD4⁺CD25⁺FoxP3⁺ Treg cells. The severity of the autoimmune syndromes caused by deficiencies in FoxP3 - scurfy in mice and IPEX in humans - highlights its central role (reviewed in (3)). Treg cells also differentiate extrathymically from conventional T cells and this differentiation is strongly modulated by cytokines such as IL-2 and TGF- β (4-6). These Treg cells have been termed peripheral Treg (pTreg) and several Ag-induced pTreg cell populations, with IL-10 based regulatory activity, appear to have critical *in vivo* functions (7-9). Several experimental tolerogenic settings have been shown to drive or increase expansion/differentiation of pTreg cells *in vivo*; these include chronic activation and sub-immunogenic Ag presentation (10-12), exposure to orally administered agonist peptides (13, 14), lymphopenia-driven homeostatic expansion (15-17) and use of small molecular weight compounds such as retinoic acid and histone deacetylase inhibitors (18, 19).

Alternative strategies to promote *in vivo* generation of stable pTreg cells use the tolerogenic properties of immature dendritic cells (DCs). Indeed, DC-based therapy has been proposed to restore tolerance in the context of several autoimmune diseases (20-22). The two main strategies developed are the direct targeting of antigens to DEC-205⁺ steady state DCs (11, 23-26) and the repetitive injection of

77 tolerogenic DCs (27-29). We have previously demonstrated that repetitive injection of
78 immature and semi-mature DCs can prevent adverse clinical outcome and protect
79 mice from experimental collagen-induced arthritis (CIA) (30, 31). This protection was
80 associated with the expansion of a particular FoxP3-negative CD4⁺ Treg cell
81 population characterized by the expression of CD49b (the alpha2 subunit of the
82 adhesion molecule VLA-2) which specifically binds to collagens I, II and X (30).
83 These induced CD49b⁺ Treg cells, which secrete high levels of IL-4 and IL-10,
84 displayed strong immunosuppressive properties *in vivo*, improving established CIA
85 and attenuating delayed type hypersensitivity reactions (32, 33). Similarly, Benoist
86 and Mathis' group demonstrated that CD4⁺CD49b⁺ Treg cells, present in naïve mice,
87 were more efficient in suppressing the onset of diabetes than CD4⁺CD25⁺ Treg cells
88 (34). As with the cell population we described, these cells' effect was IL-4 and IL-10
89 dependent. Recently, Gagliani *et al.* showed that CD49b and the lymphocyte
90 activation gene 3 (LAG-3) define the IL-10-producing FoxP3-negative T regulatory
91 type 1 cells (35).

92 Altogether these data reveal a remarkable heterogeneity in pTreg cell
93 populations and define the CD49b molecule as a relevant marker for specific Treg
94 cell subsets. Interestingly, recent studies challenged the notion that FoxP3
95 expression is uniquely responsible for all aspects of the transcriptional signature of
96 CD4⁺CD25⁺ Treg cells and showed that FoxP3-independent epigenetic changes are
97 required for Treg cell function (36, 37). These results underscore the need to better
98 characterize the non-classical CD49b⁺ induced Treg cells, which are mainly FoxP3-
99 negative. We therefore investigated their suppressive mechanism *in vivo* and
100 compared it with that of CD25⁺ Treg cells in order to determine their respective
101 therapeutic capacities.

Materials and Methods

Mice

DBA/1 mice were obtained from Harlan Laboratories and were bred in our own animal facility. Transgenic mice carrying the rearranged V α 11.1 and V β 8.2 TCR chain genes isolated from a collagen-type II (Col II)-specific T cell hybridoma were kindly provided by R. Toes (LUMC, Leiden) with the approval of W. Ladiges. C57BL/6 wild type and C57BL/6 IL10^{-/-} knockout mice (KO) were obtained from Janvier (B6.129P2-IL10^{tm1Cgn}/J) and were maintained in our animal facility under specific pathogen free conditions in isolated ventilated cages. Experimental groups were obtained by crossing heterozygous mice to obtain IL10-KO and wild type littermates with the same genetic background. Experiments were performed in accordance with national guidelines and approved by the Ethics committee for Animal Research of Languedoc-Roussillon (CEEA-LR-1067) and French Health Authorities (C34-172-36).

DC generation and injections

DCs were generated as previously described (30). Briefly, bone marrow cells were harvested from the femur and tibiae of mice and washed in RPMI following red blood cells lysis. T and B cells were depleted using mouse pan T and pan B Dynabeads® (Dyna) and monocytes were removed by 4h plate adhesion. The remaining cells were cultured in complete medium (RPMI 1640 supplemented with 5% FCS, 2mM L-glutamine, 5 x 10⁻⁵ M β -mercaptoethanol, 100U/ml penicillin, 100 μ g/ml streptomycin, essential amino acids and 1 mM sodium pyruvate) with 1,000 IU/ml of rmGM-CSF (R&D Systems) and 1,000 IU/ml of rmIL-4 (R&D Systems) at 5 x 10⁵ cells/ml in 24-well plates. Culture medium was renewed at days 2 and 4. For *in vivo* experiments, DCs were harvested at day 7. Syngeneic DBA/1, IL-10 KO or wild type littermates

were injected i.p. with 0.5×10^6 DCs in 100 μ l PBS, 7, 5 and 3 days before euthanasia for splenic T cell purification.

Antibodies and FACS analysis

Spleens were harvested and single-cell suspensions were obtained by gentle passage through 70 μ m nylon mesh filters (BD Biosciences). Following red blood cells lysis using ACK buffer, suspensions were pre-blocked using purified anti-CD16/32 Ab (2.4.G2) for 10 min. For intracellular cytokine staining, cells were stimulated during 48h at 37°C with anti-CD3/anti-CD28 antibody-coated Dynabeads (DynaL Biotech ASA, Oslo, Norway). During the last 4 hours of stimulation, 50 ng/ml of phorbol 12-myristate 13-acetate (PMA), 1 μ g/ml of ionomycin and 10 μ g/ml brefeldin A (Sigma-Aldrich, Zwijndrecht, The Netherlands) was added. Subsequently, cells were stained with surface antibodies (20 min, on ice). Cells were fixed using the eBioscience permeabilization kit according to the manufacturer's procedure and subsequently stained for intracellular markers. Data acquisition was performed on a Canto II or LSR Fortessa flow cytometer (BD Biosciences, Mountain View, CA) and analyses were performed using FlowJo software.

Treg cell isolation and adoptive cell transfer experiments

Splenocytes from DC-vaccinated mice were recovered by filtration on cell strainer, washed and then CD4⁺ T cells purified by negative selection using Dynabeads. CD4 T cells were stained with anti-CD4, anti-CD49b and anti-CD25 conjugated antibodies and cell sorting was performed on FACS Aria (MRI platform Montpellier, Fig.S1). FACS-sorted CD4⁺CD25⁺CD49b⁺ T cells (purity $>95 \pm 2\%$), CD4⁺CD25⁺CD49b⁻ (purity $>96 \pm 1\%$) or CD4⁺CD25⁻CD49b⁻ T cells (purity $>96 \pm 1\%$), herein called

CD49b⁺, CD25⁺ and CD4⁺ cells, respectively, were washed and 1.5 x 10⁵ cells were injected i.v. in the tail vein of CIA mice or were used for subsequent analyses.

Gene Chip hybridization and data analysis.

Total RNA from CD4⁺, CD25⁺ and CD49b⁺ T cells isolated from DC-injected mice and non-injected mice (CD4⁺ only) were prepared using QIAGEN RNeasy Mini kit (QIAGEN). To reduce variability, we pooled cells from multiple mice (n>10) for cell-sorting, and three replicates were generated for CD25⁺ and CD49b⁺ cell groups as well as two replicates for CD4⁺ cells isolated from DC-injected and non-injected mice. All gene-expression profiles were obtained from highly purified FACS-sorted T cell populations (MRI platform Montpellier). RNA was amplified, labeled, and hybridized (IVT Express, Affymetrix) to Affymetrix M430 PM Array Strips that cover almost all known murine genes. Affymetrix microarrays were processed at the Microarray Core Facility located at the IRMB institute. All chip data were uploaded to NCBI Gene Expression Omnibus (accession number is GSE68621, <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68621>) and are publicly available. Microarray data were analyzed according to a previously described procedure (38), to define the baseline average signal using the transcriptional profile of CD4⁺ cells isolated from non-injected mice, and to calculate the differential expression variation using the transcriptional profiles of CD4⁺, CD25⁺ and CD49b⁺ T cells isolated from DC-injected mice. To perform a robust analysis of the differentially expressed genes, we used the distribution of the number of differentially expressed transcripts to determine the optimal threshold for both the co-occurrence rate and the transcript expression variation (expression variation ≥ 1.15 and occurrence of 4/4 for CD4⁺ and 6/6 for CD25⁺ and CD49b⁺) (39).

177

178 ***In vitro* suppressive experiments**

179 CFSE-labeled CD4 effector T cells (10^5) were cultured with titrated numbers of either
180 FACS-sorted Treg cells or unlabeled-T effector cells in the presence of irradiated
181 allogenic splenocytes (5×10^5) and 2-5 $\mu\text{g/ml}$ of anti-CD3 ϵ mAb (145-2C11). After 4
182 days of culture, proliferation of effector T cells was assessed by FACS. Data were
183 analyzed using FlowJo software.

184

185 **Collagen-induced arthritis (CIA) induction and evaluation**

186 Male 9-12 week-old mice were immunized at the base of the tail with 100 μg of
187 bovine or chicken Collagen type II (Col II) (MD biosciences) emulsified in CFA
188 (Pierce, complemented to 4mg/ml with Mycobacterium tuberculosis H37RA) for
189 DBA/1 or C57BL/6, respectively. To boost immunization, C57BL/6 mice received an
190 i.v. injection of one million chicken Col II (2 $\mu\text{g/ml}$)-loaded mature DCs on day 0. On
191 day 21, DBA/1 or C57BL/6 mice received a booster immunization at the base of the
192 tail with 100 μg of bovine Col II emulsified in IFA or chicken Col II emulsified in CFA,
193 respectively. Mice were i.v. injected with the FACS-sorted Treg cells on day 28. From
194 day 21, the thickness of each hind paw was measured 3 times a week with a caliper,
195 and the severity of arthritis was graded according to the clinical scale previously
196 described (40) with some modifications. Ankylosis was graded (score 5) and number
197 of inflamed digits was also added to obtain a maximal score of 10 per paw and 40 per
198 mouse. Clinical scores are represented as means \pm SEM on a given day.

199

200 **Cytokine secretion profile**

201 Supernatants of FACS-sorted T cells (100,000 cells/well) were harvested 48 hours
202 following *in vitro* stimulation and stored at -20°C until tested for the presence of
203 murine IFN- γ , IL-10, IL-4, IL-5, and IL-13. All these cytokines were quantified by
204 ELISA kits according to the manufacturer recommendations (R&D Systems).

205

206 **Th1 or Th2 polarization of T cells**

207 For *in vitro* differentiation, naïve OVA-specific CD4⁺ T cells from DO11.10 transgenic
208 mice were cultured during 3 days in Th1 (rIL-12, 10 ng/ml + anti IL-4 antibody, 5 μ g/
209 ml) or Th2 (rIL-4, 10 ng/ml + anti-IFN- γ antibody, 1.25 μ g/ml) polarizing conditions
210 with irradiated splenocytes in the presence of OVA peptide (1 μ g/ml) kindly provided
211 by A. Chavanieu.

212

213 **Statistics**

214 Data are presented as mean \pm SEM and significance was determined using
215 GraphPad Prism software (GraphPad Software). Depending on the distribution of the
216 data, parametric or non-parametric tests with appropriate comparisons were used to
217 compare groups. A one-way or repeated two-way ANOVA with a post hoc multiple
218 comparison test were used when more than two groups were compared.

219

Results

DC-induced CD49b cells display an effector memory phenotype

As we previously published (30, 32) and as clearly shown in figure S1, repetitive injections of immature DCs significantly induced CD4⁺CD49b⁺ cells (from 5 ± 0.2% to 9 ± 0.4%, p<0.0001) without modifying CD4⁺CD25⁺ cell frequencies (12 ± 0.2% to 12 ± 0.1%, NS; Fig. S1B). In naïve mice the CD4⁺CD49b⁺ cells are a heterogeneous population containing FoxP3⁺ cells (57 ± 2%) and activated CD25⁺FoxP3^{neg} cells (7 ± 0.4%). After repeated DC injection, the expanded CD4⁺CD49b⁺ population showed a significant decrease in the percentage of FoxP3 expressing cells (24 ± 1%, p<0.0001; Fig. S1B) and a significant increase in the percentage of CD25^{neg}FoxP3^{neg} cells (69 ± 0.9%, p<0.0001). These results demonstrate that the induced CD49b⁺ cells were mostly CD25^{neg} and FoxP3^{neg}. Although the frequency of CD4⁺CD25⁺ cells did not significantly change after repeated DC injection, we observed a slight increase in the frequency of these cells expressing FoxP3 (67 ± 1% to 76 ± 2%, p<0.0001). As shown in figure S1A, the analyzed populations were gated as CD4⁺CD49b⁺CD25^{+/-}, CD4⁺CD25⁺ and CD4⁺CD25^{neg}CD49b^{neg} cells and hereafter referred to as gated CD49b, CD25 and CD4 cells, respectively. The same gating strategy was used to sort the three populations.

To better characterize the DC-induced CD49b⁺ cells, we compared their cell surface phenotype with those of CD25⁺ and CD4⁺ cells. We first compared the frequency of naïve T cells (defined as CD44^{low}CD62L^{high}) and effector memory T cells (CD44^{high}CD62L^{low}) within the gated CD4, CD25 and CD49b cell populations in non-injected and DC-injected mice (Fig. 1A lower right and upper left quadrant, respectively). The percentage of naïve T cells (Fig. 1B, top panels) was considerably

lower both in the CD25⁺ (44 ± 1%) and CD49b⁺ (26 ± 1%) cell populations, than in the CD4⁺ cell population (65 ± 1%) of non-injected mice. Concomitantly, the percentages of effector memory T cells (Fig. 1B, bottom panels) were found to be higher in the CD49b⁺ cell population (48 ± 0.5%) than in the CD25⁺ and CD4⁺ cell populations (25 ± 1% and 16% ± 1%, respectively) of non-injected mice. Following DC-vaccination, we observed a slight but significant decrease in the percentage of cells with a naïve phenotype within the CD25⁺ cell population (44 ± 1% and 36 ± 1%, p<0.05) and more importantly within the CD49b⁺ cell population (26 ± 1% to 10 ± 1%, p<0.0001). These significant decreases in cells with naïve phenotype were associated with significant increases in cells with effector memory phenotype in the CD49b⁺ (48 ± 0.5% to 66 ± 2%, p<0.0001) and to a lesser extent the CD25⁺ (25 ± 1% to 33 ± 1%, p<0.05) cell populations. These data demonstrate that the CD49b⁺ T cell population induced by DC vaccination clearly displayed an effector memory phenotype whereas the CD25⁺ T cells phenotype was less impacted.

The transcriptional profiles of CD49b⁺ T cells contain multiple transcripts of the canonical Treg cell signature shared either by CD25⁺ or other Treg sub-phenotypes

To identify the genes differentially expressed by CD25⁺ and CD49b⁺, defined as prototypical Treg transcripts, we compared the gene expression patterns of highly purified T cells. The gating strategy and purity of FACS-sorted CD49b⁺, CD25⁺ and CD4⁺ populations are given in Supplemental Figure 1. We determined the differential transcriptional profiles associated with the DC-vaccination protocol by comparative analysis of the FACS-sorted CD4⁺ cells isolated from non-injected and DC-injected mice. The transcriptional profiles of DC-induced CD25⁺ and CD49b⁺ included both

the transcriptional profile associated with the CD4⁺ cell subset and the DC-vaccination induced transcripts. To focus our analysis only on CD49b⁺ and CD25⁺ specific transcripts, we removed the transcripts associated with DC vaccination found in CD4⁺. We were therefore able to compare these CD25⁺ and CD49b⁺ differential gene expression profiles with the canonical Treg cell expression signature consisting of 603 probe sets (16, 26, 37). These 603 probe sets defined by Hill *et al.*, correspond to 431 transcripts (138 down-regulated and 293 up-regulated) that revealed a mean probe set redundancy of 1.4 in their study. In our study, the precise and robust analysis of the differentially expressed transcripts is underscored by the mean global score for probe redundancy of 2.0. We found 79 differentially expressed transcripts in the CD49b⁺ cells (18 down-regulated and 61 up-regulated) and 128 differentially expressed transcripts in the CD25⁺ cells (28 down-regulated and 100 up-regulated) all in common with the canonical Treg signature, with similar modulation described by Hill *et al.* (Fig. 2A). Interestingly the CD25⁺ and CD49b⁺ cell populations shared 59 differentially expressed transcripts (11 down-regulated and 48 up-regulated) (Fig 2B), corresponding to 74.6% of the differentially expressed transcripts found in CD49b⁺, therefore underscoring the similarities between CD49b⁺ and CD25⁺ Treg cells. Similar transcriptional expression variations were observed between CD49b⁺ and CD25⁺ Treg cells with similar modulations to those described by Hill *et al.* The common transcriptional pattern between CD49b⁺ and CD25⁺ contained several prototypical Treg transcripts, including *Itgae*, *Klrg1*, *Nrp1*, *Gzmb*, *Ebi3*, *Entpd1*, *Dusp4*, *Socs2*, *Ahr*, *Swap70*.

We also found that each cell population uniquely expressed several canonical Treg cell signature transcripts: 69 for CD25⁺ (17 down-regulated and 52 up-regulated) and 20 for CD49b⁺ (7 down-regulated and 13 up-regulated) (Fig. 2A and

Fig. S2). Interestingly among the transcripts specific for CD49b⁺, we found *AcoT7*, *LXN*, *5830474E16Rik*, *Gpr34*, *Pros1* and *Ndr1*. These transcripts have previously been described as differentially expressed in conventional Treg cells isolated from spleen, and highly expressed in CD103⁺ and KLRG1⁺ Treg cells (26). Altogether, our results demonstrate that the CD49b⁺ transcriptional signature contains prototypical Treg cell transcripts shared by either CD25⁺ or other Treg cell sub-phenotypes.

CD49b⁺ Treg cells express several canonical markers of CD25⁺FoxP3⁺ Treg cells.

To further characterize and compare the phenotypes of the DC-induced CD49b⁺ and CD25⁺ cells isolated from the same DC-vaccinated mice, we performed 6-10 colors cytometric analyses. We showed that, despite weakly expressing CD25 and the master regulator transcription factor FoxP3 (Fig. S1), CD49b⁺ cells express markers commonly used to characterize CD25⁺FoxP3⁺ Treg cells, including CD103, KLRG1, CTLA-4, latency associated peptide (LAP) and glucocorticoid-induced TNFR family related gene (GITR) (Fig. 3). Interestingly, CD49b⁺ cells also expressed programmed cell death-1 (PD1), shown to play an important role in pTreg cell induction and function (41), although at a lower level than that in CD25⁺ cells (Fig. 3A). Moreover, expression of LAG-3, KLRG1 and CD103 molecules was in contrast significantly higher in CD49b⁺ than in CD25⁺ cells (Fig. 3A). Within the CD49b⁺ cell population, we noted that LAG-3 expression was mostly restricted to the FoxP3^{neg} cells, whereas KLRG1 and CD103 expressions were found in both FoxP3⁺ and FoxP3^{neg} cells.

Several molecules sustaining the Treg cell suppressive function are known to be highly expressed following activation. As CD25 and CD49b expressions are also

modulated following activation, we first purified the T cells from DC-vaccinated mice by FACS-sorting them (Fig. S1) and the three resulting populations were analyzed 48 hours following *in vitro* stimulation. Phenotypic analysis of activated T cells clearly showed that all T cells acquired CD25 expression, and that half of the CD25⁺ Treg cells were FoxP3⁺ compared to less than 4% of the CD49b⁺ Treg cells (Fig. 3B). Interestingly, compared to the CD25⁺ T cell population, that of the CD49b⁺ T cells displayed higher percentages or mean fluorescence intensity (MFI) of several markers commonly expressed by Treg cells. These markers included Granzyme B (GrB), GITR, inducible T-cell costimulator (ICOS), LAP and IL-10 in terms of percentages, and CTLA-4 for MFI. We narrowed our focus down to effector mechanisms by comparing the phenotype of IL-10 secreting T cells (gated within the CD49b⁺ cell population) with that of FoxP3⁺ cells (gated within the CD25⁺ cell population) (Fig. S3). Interestingly, the FoxP3⁺ cell sub-population displayed a higher percentage of cells expressing LAP than did the IL-10 secreting sub-population (31 ± 8% versus 10 ± 0.5% respectively, p=0.008). Conversely, GITR (96 ± 0.5% versus 78 ± 3%, p= 0.026), CTLA-4 (97 ± 0.1% versus 84 ± 5%, p= 0.02) and GrB (31 ± 8% versus 2.5 ± 0.3%, p=0.010) were more frequently expressed among the IL-10 secreting CD49b⁺ Treg cells than in the FoxP3⁺CD25⁺ cell sub-population. These results suggest that, besides IL-10, these three molecules could play an important role in the CD49b⁺ suppressive function (Fig. S3).

Peripherally induced CD49b⁺ cells express Neuropilin-1 without co-expressing Helios.

Neuropilin-1 (Nrp-1) was proposed as a Treg cell surface marker in 2004 (42) and its coordinated expression along with Helios, an Ikaros family transcription factor,

was more recently suggested for use in distinguishing thymic derived from inducible Foxp3⁺CD25⁺ Treg cells (43-46). Indeed, pTreg cell populations generated *in vivo* displayed reduced Nrp-1 expression compared with tTreg cells, indicating Nrp-1 as a tTreg specific marker (26). As previously published for NOD and C57BL/6 mice (43), we showed in DBA/1 mice that the majority of CD25⁺ cells express concurrently Nrp-1 and Helios (56 ± 3%) (Fig. 4). Interestingly, Nrp-1 expression was high (58 ± 1%) but Helios expression was significantly lower (15 ± 1%) in CD49b⁺ cells. Moreover, we observed that CD49b⁺Helios⁺ cells co-expressed Nrp-1⁺ and FoxP3⁺ suggesting that among the CD49b⁺ cell population, almost 20% of cells could be considered as natural tTreg cells based on the concomitant expression of Helios, Nrp-1 and FoxP3 (Fig.4). Altogether, our results show that induced FoxP3^{neg}CD49b⁺ Treg cells are positive for Nrp-1 but do not co-express Helios, as expected for induced pTreg cells.

Peripheral induced CD49b cells express Th1- and Th2-specific transcriptional factors and cytokines

Recent evidence suggests that the capacity of Treg cells to control polarized settings can be associated with the expression of specific transcription factors, such as T-bet, interferon regulatory factor 4 (IRF4) and STAT3 to control Th1, Th2 and Th17 responses respectively (47-49). Treg cells expressing these transcription factors can partially mimic the phenotype of the effector T cells, providing them with particular homing, survival, or functional properties (50). It has been demonstrated that 25% of FoxP3⁺ compared to only 5% of FoxP3^{neg} Treg cells isolated from spleen express the canonical Th2 transcription factor Gata3 (51). These authors showed that the expression of Gata3 controlled unbalanced polarization and inflammatory cytokine production in Treg cells, and that it was required for the maintenance of

FoxP3 high level expression and promoted the accumulation of Treg cells at inflamed sites (51). In our study in DBA/1 mice, we observed Gata3 expression in $8 \pm 1\%$ of the CD25⁺ cells and in $47 \pm 2\%$ of the CD49b⁺ cell population (Fig. 5A). Furthermore, we observed that only the DC-induced CD49b⁺ cells displayed a considerable proportion of double positive staining for T-bet and Gata3 ($25 \pm 1.5\%$), in contrast with the CD4⁺ and CD25⁺ cells ($2 \pm 0.2\%$ for both populations) (Fig. 5A, right panel). This DC-induced increase in the number of CD49b⁺ cells expressing both T-bet and Gata3 was statistically significant ($25 \pm 1.5\%$ versus $2 \pm 0.2\%$, $p < 0.0001$).

C-Maf was the first Th2-specific transcription factor identified and has been shown to play a critical role in trans-activating IL-4 and IL-10 expression during Th17 polarization. The ligand-activated transcription factor aryl hydrocarbon receptor (AhR), like the proto-oncogene Maf, was shown to be strongly induced during Tr1 cell differentiation with similarly high levels of expression found in both Tr1 and Th17 cells (52). We thus evaluated the expression of c-Maf and AhR in CD49b⁺ cells and found them in $53 \pm 2\%$ and $82 \pm 1\%$ respectively, compared to in only $38 \pm 1\%$ and $39 \pm 2\%$ respectively of the CD25⁺ population (Fig. 5B).

To further characterize the cytokine secretion profile we quantified the level of cytokine secretion in the supernatant of highly purified FACS-sorted cells following their *in vitro* activation. Besides the high level of IL-10 secretion (19 ± 7 ng/ml), we measured significantly elevated secretion levels of other type 2 cytokines, including IL-4 (10 ± 2 ng/ml), IL-5 (18 ± 2 ng/ml) and IL-13 (31 ± 0.5 ng/ml), as well as a relatively high amount of IFN- γ (3 ± 1 ng/ml) in the supernatant of the CD49b⁺ T cell population. These results revealed an obvious type 2 dominant cytokine profile for the CD49b⁺ Treg cells and underscored their dissimilarity with Tr1 cells, which secrete high levels of IL-10 without concomitant secretion of IL-4 (40, 53).

Polyclonal and Ag-specific CD49b⁺ Treg cells have potent *in vitro* and *in vivo* suppressive capacities

We compared the *in vitro* potential of CD49b⁺ and CD25⁺ Treg cells to functionally suppress the proliferation of CD4⁺ T cells by co-cultivating Treg and responder cell populations stimulated by a polyclonal T cell receptor stimulator (anti-CD3 mAb) and in the presence of antigen-presenting cells. Addition of CD49b⁺ or CD25⁺ Treg cells reduced the proliferation, as measured by the CFSE dilution, in a dose-dependent manner thus confirming their potent *in vitro* suppressive capacities (Fig 6A).

We previously demonstrated the *in vivo* therapeutic potential of CD49b⁺ Treg cells to protect against (30) as well as to improve the condition of established arthritis (32). To further investigate the therapeutic potential of CD49b⁺ Treg cells, we compared their protective effect with that of CD25⁺ Treg cells isolated from the same DBA/1 mice and with CD49b⁺ Treg cells isolated from Col II-specific T cell transgenic mice (TBC). We repeatedly injected syngeneic mice intraperitoneally with 0.5×10^6 DCs the week before their euthanasia. CD4⁺ T cells were pre-purified and the Treg cells were FACS-sorted to obtain >98% pure population. The FACS-sorted populations were adoptively transferred intravenously into collagen-induced arthritic (CIA) mice on day 28, at the onset of the clinical signs. In this experimental setting that mimics the clinical situation, we observed a similar decrease of arthritis severity in mice injected with either of the polyclonal Treg cells, CD49b⁺ or CD25⁺, isolated from the same DBA/1 mouse, or with the antigen-specific CD49b⁺ Treg cells (CD49b TBC, Fig. 6B). Similar results were obtained in several independent experiments, and we performed robust statistical analyses using relative arthritic scores calculated

using the mean of the PBS-treated mice as 100% disease severity for each experiment. We included in these experiments a control group of mice, which were injected with the CD4⁺ cell population. As shown in figure 6C, injection of polyclonal CD49b⁺ Treg cells markedly and significantly decreased the disease severity compared with PBS-treated or CD4⁺-treated mice. We observed a tendency towards decreased disease severity after injection of the CD25⁺ Treg cells or of the antigen-specific CD49b⁺ Treg cells isolated from TBC mice, however these decreases were not significant. These results in the CIA experimental model suggest that the use of CD49b⁺ Treg cells may represent the best therapeutic strategy, over the use of natural CD25⁺ Treg cells.

Finally, to further investigate the *in vivo* suppressive mechanism, we performed similar adoptive transfer experiments with CD49b⁺ Treg cells isolated from IL-10 KO mice. In this experimental setting, CD49b⁺ Treg cells were isolated from IL-10 KO or wild-type littermates and injected on day 28 into arthritis-induced C57BL/6 mice. As clearly shown in figure 6D, injection of CD49b⁺ isolated from wild-type littermates significantly protected mice from arthritis whereas IL-10 deficient CD49b⁺ Treg cells were less protective. These results underscore the partial involvement of IL-10 secretion in the CD49b⁺ Treg protective effect and suggest that alternative mechanisms might be important for their *in vivo* suppressive function.

Discussion

The discovery that Treg cells can control autoimmune inflammatory responses has led to great enthusiasm for their clinical application in autoimmune diseases such as rheumatoid arthritis (RA). The hope is that the impaired Treg cell differentiation may be corrected by adoptive transfer of *in vitro*-generated autologous Treg cells or by immunotherapeutic strategies triggering an increase in the number and/or an improved functioning of endogenous Treg cells.

In vitro generation of autologous Treg cells could be a treatment option for multiple autoimmune diseases, including experimental autoimmune encephalomyelitis, diabetes, colitis, and lupus (54-56). However, this approach is quite challenging because it is difficult to generate and/or expand Treg cells with specific Ag specificity, especially when the immunodominant epitopes are uncharacterized, such as in RA. Nevertheless, *in vitro* expansion of Col II-specific Tr1 cells isolated from RA patients was recently demonstrated (57). Pre-clinical proof-of-concept concerning the therapeutic potential of *in vitro* generated Col II-specific Tr1 cells has also been recently validated in two experimental models of arthritis (40). Altogether these results support the therapeutic use of ex-vivo expanded autologous Ag-specific Treg cells in RA.

However, some evidence suggests that Treg cells generated *in vitro* are phenotypically and functionally unstable, whereas those induced *in vivo* are epigenetically more stable and would lead to a longer-lasting therapeutic effect (4, 58, 59). The *in vivo*-induced Treg cells are usually Ag specific, which implies a likely more efficient effect in treating autoimmune diseases. In RA patients, TNF- α blocking antibodies have been described as an effective way to stimulate the induction of peripheral FoxP3⁺ Treg cells, overcoming the impaired peripheral Treg cell

differentiation (60). For all these reasons, the development of strategies to promote *in vivo* generation of Ag-specific Treg cells appears crucial for the treatment of autoimmune diseases.

The aim of our study was to better characterize a particular sub-population of *in vivo*-induced CD49b⁺ Treg cells. We demonstrated that this particular Treg cell subset expresses several canonical markers of Treg cells while being mostly negative for CD25 and FoxP3, which are routinely used to identify Treg cells. We first demonstrated that 30% of the Treg cell signature was found in the CD25⁺ Treg cell specific expression profile. Indeed, the Treg cell canonical signature is a composite signature derived from Treg cells isolated from several lymphoid organs (37). This bulk of Treg cell sub-phenotypes could explain the lack of complete overlapping with the specific transcriptional profile of CD25⁺ cells in our study. A similar lack of complete overlapping has previously been observed when comparing the transcriptional profile of converted FoxP3⁺ Treg cells with the canonical Treg cell signature (26). Interestingly, the induced CD49b⁺ Treg cells shared a transcriptional profile common to CD25⁺ Treg cells and the canonical Treg cell signature. We showed that 75% of the differentially expressed transcripts found in CD49b⁺ T cells were common with those found in CD25⁺ T cells, underscoring the similarities between CD49b⁺ and CD25⁺ Treg cells. Indeed, we demonstrated that these cells share a common signature of 59 prototypical Treg cell transcripts including effector molecules and transcription factors. Several transcripts from this common signature have been proposed as promising candidates to specifically discriminate between Ag-induced and homeostatically converted Treg cells, including *Itgae*, *Ctla4*, *Entpd1* (CD39), *Ebi3* (a component of IL35), *Irf4*, α E β 7 (CD103) and *Klrg1* (a member of the killer cell lectin-like receptor family). The CD49b⁺ Treg cell transcriptional profile also

contained several specific transcripts in common with the canonical Treg signature. These results suggest an overlap of the transcriptional profile of CD49b⁺ Treg cells with several other Treg sub-phenotypes.

We validated by FACS analyses the common expression of several markers between CD25⁺ and CD49b⁺ cells that were differentially expressed compared with CD4⁺. Among these markers, CD49b and KLRG1, both considered as NK cell markers and minimally expressed on conventional CD4⁺ T cells, were previously observed in an extrathymically derived subset of CD4⁺CD25⁺FoxP3⁺ Treg cells (61). Within the sub-population of CD25⁺FoxP3⁺ Treg cells in the spleen, KLRG1⁺ Treg cells were previously shown to display a more activated phenotype (CD69⁺CD62L^{low}CD103⁺CD44^{high}) than KLRG1^{neg} Treg cells. Furthermore, cell-surface staining of homeostatically converted FoxP3⁺ cells revealed them as uniformly CD103⁺, an excellent marker for identifying *in vivo*-activated FoxP3⁺CD4⁺ Treg cells, and that 50% of the cells expressed KLRG1 (26). We showed that the two markers, KLRG1 and CD103, were expressed on CD49b⁺ and CD25⁺ cells and, as previously observed for the CD4⁺CD25⁺FoxP3⁺ Treg cells, were associated with an activated phenotype for the CD49b cells. Similarly, Nrp-1 was previously described on a population of activated/memory FoxP3^{neg}Nrp-1⁺ in secondary lymphoid organs and inflamed tissues, which could imply that the expression of Nrp-1 is associated with the CD49b⁺ activated/memory phenotype. Finally, the lack of concomitant expression of Nrp-1 and Helios as well as their effector/memory phenotype confirm the peripheral origin of these cells.

Initially characterized as a Th2 specific cytokine, IL-10 has since been found expressed by almost all CD4⁺ T cells, including CD25⁺FoxP3⁺ Treg cells and Tr1 cells, but also Th1, Th2 and Th17 cells, in order to promote immune homeostasis.

515 Previous mouse studies have described the collaborative actions of c-Maf with AhR
516 and the ICOS receptor ligation that drive IL-10 expression and promote Tr1
517 differentiation (52, 62). We demonstrated in this study that the CD49b⁺ Treg cells
518 highly express these three molecules suggesting that, similarly to Tr1 cells, several
519 transcriptional pathways, associated with high secretion of IL-10, are activated.
520 CD49b⁺ cells are also positive for the Th2 specific transcription factor Gata3 and 30%
521 of the cells are double positive for T-bet and Gata3 with concomitant secretion of
522 IFN- γ and Th2 cytokines. The co-expression of T-bet and Gata3 has been previously
523 observed *in vivo* following viral infection and this hybrid phenotype appeared to be
524 stable (63). Altogether our results suggest that the CD49b⁺ cells display a balanced
525 Th2/Th1 phenotype that could endow them with specific properties to better control
526 effector T cell responses.

527 Other similarities and differences between IL-10-secreting CD49b⁺ Treg cells
528 and Tr1 cells can be discussed. Co-expression of CD49b and LAG-3 has been
529 recently proposed as specific for Tr1 cells (35). In our experimental setting, only 5 to
530 10% of CD49b⁺ Treg cells were positive for LAG-3 before *in vitro* activation and
531 interestingly CD49b⁺LAG-3⁺ cells are mostly FoxP3 negative cells like Tr1 cells.
532 Furthermore Tr1 cells are reported to be induced at mucosal sites in response to
533 antigen stimulation in the presence of IL-10. We observed that IL-10 deficient DCs
534 promoted IL-10 secreting CD49b⁺ Treg cell expansion in several lymphoid organs of
535 wild type animals suggesting that, in contrast to Tr1 cells (64), the IL-10 secretion by
536 DCs is dispensable for the expansion of CD49b⁺ (P. Louis-Plence, unpublished data).
537 Altogether our results suggest that the CD49b⁺ Treg cells constitute a Treg sub-
538 phenotype that shares similarities with the CD25⁺ Treg cells as well as with the Tr1

cells, and should be considered alongside other sub-phenotypes as homeostatically converted or antigen-induced.

Here we have investigated the suppressive function of CD25⁺ and CD49b⁺ Treg cell populations *in vitro* and *in vivo*, in the experimental model of CIA. *In vitro*, both Treg cell populations similarly suppressed the T cell proliferation. To compare their therapeutic potential in CIA, we injected CD25⁺, polyclonal CD49b⁺ or Col II-specific CD49b⁺ Treg cells at the onset of clinical signs of arthritis. As previously described (32), we demonstrated a significant reduction of these clinical signs following injection of polyclonal CD49b⁺ Treg cells. Although not significant, we also observed decreased clinical signs following injection of CD25⁺ or Col II-specific CD49b⁺ Treg cells. Our results suggest that following their activation by self-Ag(s), the CD49b⁺ regulatory T cells display a potent bystander suppressive function and as polyclonal *in vivo*-expanded Treg cells, they could be a better alternative to classical Treg cells for arthritis treatment. The suppressive function of CD49b⁺ Treg cells was found to be partially dependent on IL-10 secretion. Moreover expression of several canonical Treg markers, implicated in the Treg suppressive function, suggests that other molecules might also play a role in the CD49b suppressive activity. Indeed, GrB and CTLA-4 have been shown to play a crucial role in the suppressive function of conventional CD25⁺FoxP3⁺ Treg cells and thus might also play an important role in the suppressive function of CD49b⁺ Treg cells. Furthermore, CD103 expression could also be implicated in their suppressive function as its expression was shown to be responsible for the retention of Treg cells in inflamed tissue by interaction with its ligand E-cadherin (65, 66). Finally, expression of the alpha2 integrin CD49b itself, could also be important for their function since it was demonstrated that this integrin is required for the migration of memory CD4 T-cell precursors into their survival

niches of the bone marrow (67). Since VLA-2 also binds collagen II, expression of CD49b could provide Treg cells with particular homing, survival, or more potent suppressive function in the context of arthritis since collagen II is expressed by the damaged cartilage.

In this study, we have provided an in-depth characterization of the CD49b⁺ Treg cells, underscoring their similarities with other Treg sub-phenotypes and highlighting specific expression patterns for several markers including ICOS, CTLA-4 and GrB. The expression of these canonical Treg markers strongly supports the notion that several suppressive mechanisms could be FoxP3-independent. Their potent suppressive activity *in vivo*, higher than that of the classical CD25⁺ Treg cells, underscores the need to select appropriate Treg subsets for a given clinical application and supports their therapeutic application in RA.

Acknowledgments

We thank Myriam Boyer and Christophe Duperray (Montpellier RIO Imaging platform) for performing cell-sorting experiments with the FACSARIA and the ECELLFRANCE national infrastructure for providing the LSR Fortessa cytometer. We also thank Véronique Pantesco for gene-chip hybridization and the animal facility staff located at the INM institute in Montpellier (RAM network) for their expert care of the mice colonies.

References

1. Klein, L., and K. Jovanovic. Regulatory T cell lineage commitment in the thymus. *Semin Immunol* 23:401-409.
2. Wing, K., and S. Sakaguchi. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. *Nat Immunol* 11:7-13.
3. Ziegler, S. F. 2006. FOXP3: of mice and men. *Annu Rev Immunol* 24:209-226.

4. Chen, Q., Y. C. Kim, A. Laurence, G. A. Punkosdy, and E. M. Shevach. 2003. IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3+ T cells in vivo. *J Immunol* 186:6329-6337.
5. Curotto de Lafaille, M. A., and J. J. Lafaille. 2009. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? *Immunity* 30:626-635.
6. Zheng, S. G., J. Wang, P. Wang, J. D. Gray, and D. A. Horwitz. 2007. IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. *J Immunol* 178:2018-2027.
7. O'Garra, A., and P. Vieira. 2004. Regulatory T cells and mechanisms of immune system control. *Nat Med* 10:801-805.
8. Hawrylowicz, C. M., and A. O'Garra. 2005. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. *Nat Rev Immunol* 5:271-283.
9. Roncarolo, M. G., S. Gregori, M. Battaglia, R. Bacchetta, K. Fleischhauer, and M. K. Levings. 2006. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. *Immunol Rev* 212:28-50.
10. Verginis, P., K. A. McLaughlin, K. W. Wucherpfennig, H. von Boehmer, and I. Apostolou. 2008. Induction of antigen-specific regulatory T cells in wild-type mice: visualization and targets of suppression. *Proc Natl Acad Sci U S A* 105:3479-3484.
11. Kretschmer, K., I. Apostolou, D. Hawiger, K. Khazaie, M. C. Nussenzweig, and H. von Boehmer. 2005. Inducing and expanding regulatory T cell populations by foreign antigen. *Nat Immunol* 6:1219-1227.
12. Apostolou, I., and H. von Boehmer. 2004. In vivo instruction of suppressor commitment in naive T cells. *J Exp Med* 199:1401-1408.
13. Mucida, D., N. Kutchukhidze, A. Erazo, M. Russo, J. J. Lafaille, and M. A. Curotto de Lafaille. 2005. Oral tolerance in the absence of naturally occurring Tregs. *J Clin Invest* 115:1923-1933.
14. Curotto de Lafaille, M. A., N. Kutchukhidze, S. Shen, Y. Ding, H. Yee, and J. J. Lafaille. 2008. Adaptive Foxp3+ regulatory T cell-dependent and -independent control of allergic inflammation. *Immunity* 29:114-126.
15. Knoechel, B., J. Lohr, E. Kahn, J. A. Bluestone, and A. K. Abbas. 2005. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. *J Exp Med* 202:1375-1386.
16. Haribhai, D., W. Lin, B. Edwards, J. Ziegelbauer, N. H. Salzman, M. R. Carlson, S. H. Li, P. M. Simpson, T. A. Chatila, and C. B. Williams. 2009. A central role for induced regulatory T cells in tolerance induction in experimental colitis. *J Immunol* 182:3461-3468.
17. Curotto de Lafaille, M. A., A. C. Lino, N. Kutchukhidze, and J. J. Lafaille. 2004. CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion. *J Immunol* 173:7259-7268.
18. Benson, M. J., K. Pino-Lagos, M. Roseblatt, and R. J. Noelle. 2007. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. *J Exp Med* 204:1765-1774.
19. Edwards, A. J., and S. L. Pender. Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases. *Biochem Soc Trans* 39:1092-1095.
20. Amodio, G., A. Mugione, A. M. Sanchez, P. Vigano, M. Candiani, E. Somigliana, M. G. Roncarolo, P. Panina-Bordignon, and S. Gregori. HLA-G expressing DC-10 and CD4(+) T cells accumulate in human decidua during pregnancy. *Hum Immunol* 74:406-411.

- 638 21. Gross, C. C., and H. Wiendl. Dendritic cell vaccination in autoimmune disease. *Curr*
639 *Opin Rheumatol* 25:268-274.
- 640 22. Hilkens, C. M., J. D. Isaacs, and A. W. Thomson. 2010. Development of dendritic cell-
641 based immunotherapy for autoimmunity. *Int Rev Immunol* 29:156-183.
- 642 23. Mahnke, K., Y. Qian, J. Knop, and A. H. Enk. 2003. Induction of CD4+/CD25+
643 regulatory T cells by targeting of antigens to immature dendritic cells. *Blood*
644 101:4862-4869.
- 645 24. Kretschmer, K., T. S. Heng, and H. von Boehmer. 2006. De novo production of
646 antigen-specific suppressor cells in vivo. *Nat Protoc* 1:653-661.
- 647 25. Idoyaga, J., C. Fiorese, L. Zbytnuik, A. Lubkin, J. Miller, B. Malissen, D. Mucida, M.
648 Merad, and R. M. Steinman. Specialized role of migratory dendritic cells in peripheral
649 tolerance induction. *J Clin Invest* 123:844-854.
- 650 26. Feuerer, M., J. A. Hill, K. Kretschmer, H. von Boehmer, D. Mathis, and C. Benoist.
651 2010. Genomic definition of multiple ex vivo regulatory T cell subphenotypes. *Proc*
652 *Natl Acad Sci U S A* 107:5919-5924.
- 653 27. Jonuleit, H., E. Schmitt, G. Schuler, J. Knop, and A. H. Enk. 2000. Induction of
654 interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties
655 by repetitive stimulation with allogeneic immature human dendritic cells. *J Exp Med*
656 192:1213-1222.
- 657 28. Menges, M., S. Rossner, C. Voigtlander, H. Schindler, N. A. Kukutsch, C. Bogdan, K.
658 Erb, G. Schuler, and M. B. Lutz. 2002. Repetitive injections of dendritic cells matured
659 with tumor necrosis factor alpha induce antigen-specific protection of mice from
660 autoimmunity. *J Exp Med* 195:15-21.
- 661 29. Petzold, C., J. Riewaldt, T. Koenig, S. Schallenberg, and K. Kretschmer. Dendritic cell-
662 targeted pancreatic beta-cell antigen leads to conversion of self-reactive CD4(+) T
663 cells into regulatory T cells and promotes immunotolerance in NOD mice. *Rev Diabet*
664 *Stud* 7:47-61.
- 665 30. Charbonnier, L. M., L. M. van Duivenvoorde, F. Apparailly, C. Cantos, W. G. Han, D.
666 Noel, C. Duperray, T. W. Huizinga, R. E. Toes, C. Jorgensen, and P. Louis-Plence. 2006.
667 Immature dendritic cells suppress collagen-induced arthritis by in vivo expansion of
668 CD49b+ regulatory T cells. *J Immunol* 177:3806-3813.
- 669 31. van Duivenvoorde, L. M., P. Louis-Plence, F. Apparailly, E. I. van der Voort, T. W.
670 Huizinga, C. Jorgensen, and R. E. Toes. 2004. Antigen-specific immunomodulation of
671 collagen-induced arthritis with tumor necrosis factor-stimulated dendritic cells.
672 *Arthritis Rheum* 50:3354-3364.
- 673 32. Charbonnier, L. M., W. G. Han, J. Quentin, T. W. Huizinga, J. Zwerina, R. E. Toes, C.
674 Jorgensen, and P. Louis-Plence. 2010. Adoptive transfer of IL-10-secreting
675 CD4+CD49b+ regulatory T cells suppresses ongoing arthritis. *J Autoimmun* 34:390-
676 399.
- 677 33. Han, W. G., E. I. van der Voort, H. el Bannoudi, P. Louis-Plence, T. W. Huizinga, and R.
678 E. Toes. 2010. DX5(+)CD4(+) T cells modulate cytokine production by CD4(+) T cells
679 towards IL-10 via the production of IL-4. *Eur J Immunol* 40:2731-2740.
- 680 34. Gonzalez, A., I. Andre-Schmutz, C. Carnaud, D. Mathis, and C. Benoist. 2001. Damage
681 control, rather than unresponsiveness, effected by protective DX5+ T cells in
682 autoimmune diabetes. *Nat Immunol* 2:1117-1125.
- 683 35. Gagliani, N., C. F. Magnani, S. Huber, M. E. Gianolini, M. Pala, P. Licona-Limon, B. Guo,
684 D. R. Herbert, A. Bulfone, F. Trentini, C. Di Serio, R. Bacchetta, M. Andreani, L.

- 685 Brockmann, S. Gregori, R. A. Flavell, and M. G. Roncarolo. 2013. Coexpression of
686 CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. *Nat Med*
687 19:739-746.
- 688 36. Ohkura, N., M. Hamaguchi, H. Morikawa, K. Sugimura, A. Tanaka, Y. Ito, M. Osaki, Y.
689 Tanaka, R. Yamashita, N. Nakano, J. Huehn, H. J. Fehling, T. Sparwasser, K. Nakai, and
690 S. Sakaguchi. T cell receptor stimulation-induced epigenetic changes and Foxp3
691 expression are independent and complementary events required for Treg cell
692 development. *Immunity* 37:785-799.
- 693 37. Hill, J. A., M. Feuerer, K. Tash, S. Haxhinasto, J. Perez, R. Melamed, D. Mathis, and C.
694 Benoist. 2007. Foxp3 transcription-factor-dependent and -independent regulation of
695 the regulatory T cell transcriptional signature. *Immunity* 27:786-800.
- 696 38. Chuchana, P., D. Marchand, M. Nugoli, C. Rodriguez, N. Molinari, and J. A. Garcia-
697 Sanz. 2007. An adaptation of the LMS method to determine expression variations in
698 profiling data. *Nucleic Acids Res* 35:e71.
- 699 39. Chuchana, P., P. Holzmüller, F. Vezilier, D. Berthier, I. Chantal, D. Severac, J. L.
700 Lemesre, G. Cuny, P. Nirde, and B. Bucheton. 2010. Intertwining threshold settings,
701 biological data and database knowledge to optimize the selection of differentially
702 expressed genes from microarray. *PLoS One* 5:e13518.
- 703 40. Asnagli, H., D. Martire, N. Belmonte, J. Quentin, H. Bastian, M. Boucard-Jourdin, P. B.
704 Fall, A. L. Mausset-Bonnefont, A. Mantello-Moreau, S. Rouquier, I. Marchetti, C.
705 Jorgensen, A. Foussat, and P. Louis-Plence. 2014. Type 1 regulatory T cells specific for
706 collagen-type II as an efficient cell-based therapy in arthritis. *Arthritis Res Ther*
707 16:R115.
- 708 41. Francisco, L. M., V. H. Salinas, K. E. Brown, V. K. Vanguri, G. J. Freeman, V. K. Kuchroo,
709 and A. H. Sharpe. 2009. PD-L1 regulates the development, maintenance, and function
710 of induced regulatory T cells. *J Exp Med* 206:3015-3029.
- 711 42. Bruder, D., M. Probst-Keppler, A. M. Westendorf, R. Geffers, S. Beissert, K. Loser, H.
712 von Boehmer, J. Buer, and W. Hansen. 2004. Neuropilin-1: a surface marker of
713 regulatory T cells. *Eur J Immunol* 34:623-630.
- 714 43. Yadav, M., C. Louvet, D. Davini, J. M. Gardner, M. Martinez-Llordella, S. Bailey-
715 Bucktrout, B. A. Anthony, F. M. Sverdrup, R. Head, D. J. Kuster, P. Rumsinski, D. Weiss,
716 D. Von Schack, and J. A. Bluestone. 2012. Neuropilin-1 distinguishes natural and
717 inducible regulatory T cells among regulatory T cell subsets in vivo. *J Exp Med*
718 209:1713-1722, S1711-1719.
- 719 44. Weiss, J. M., A. M. Bilate, M. Gobert, Y. Ding, M. A. Curotto de Lafaille, C. N.
720 Parkhurst, H. Xiong, J. Dolpady, A. B. Frey, M. G. Ruocco, Y. Yang, S. Floess, J. Huehn,
721 S. Oh, M. O. Li, R. E. Niec, A. Y. Rudensky, M. L. Dustin, D. R. Littman, and J. J. Lafaille.
722 2012. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not
723 mucosa-generated induced Foxp3+ T reg cells. *J Exp Med* 209:1723-1742, S1721.
- 724 45. Thornton, A. M., P. E. Korty, D. Q. Tran, E. A. Wohlfert, P. E. Murray, Y. Belkaid, and E.
725 M. Shevach. Expression of Helios, an Ikaros transcription factor family member,
726 differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. *J*
727 *Immunol* 184:3433-3441.
- 728 46. Singh, K., M. Hjort, L. Thorvaldson, and S. Sandler. Concomitant analysis of Helios and
729 Neuropilin-1 as a marker to detect thymic derived regulatory T cells in naive mice. *Sci*
730 *Rep* 5:7767.

47. Zheng, Y., A. Chaudhry, A. Kas, P. deRoos, J. M. Kim, T. T. Chu, L. Corcoran, P. Treuting, U. Klein, and A. Y. Rudensky. 2009. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. *Nature* 458:351-356.
48. Koch, M. A., G. Tucker-Heard, N. R. Perdue, J. R. Killebrew, K. B. Urdahl, and D. J. Campbell. 2009. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. *Nat Immunol* 10:595-602.
49. Chaudhry, A., D. Rudra, P. Treuting, R. M. Samstein, Y. Liang, A. Kas, and A. Y. Rudensky. 2009. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. *Science* 326:986-991.
50. Campbell, D. J., and M. A. Koch. Phenotypical and functional specialization of FOXP3+ regulatory T cells. *Nat Rev Immunol* 11:119-130.
51. Wohlfert, E. A., J. R. Grainger, N. Bouladoux, J. E. Konkel, G. Oldenhove, C. H. Ribeiro, J. A. Hall, R. Yagi, S. Naik, R. Bhairavabhotla, W. E. Paul, R. Bosselut, G. Wei, K. Zhao, M. Oukka, J. Zhu, and Y. Belkaid. GATA3 controls Foxp3(+) regulatory T cell fate during inflammation in mice. *J Clin Invest* 121:4503-4515.
52. Pot, C., H. Jin, A. Awasthi, S. M. Liu, C. Y. Lai, R. Madan, A. H. Sharpe, C. L. Karp, S. C. Miaw, I. C. Ho, and V. K. Kuchroo. 2009. Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. *J Immunol* 183:797-801.
53. Magnani, C. F., G. Alberigo, R. Bacchetta, G. Serafini, M. Andreani, M. G. Roncarolo, and S. Gregori. 2011. Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. *Eur J Immunol* 41:1652-1662.
54. Selvaraj, R. K., and T. L. Geiger. 2008. Mitigation of experimental allergic encephalomyelitis by TGF-beta induced Foxp3+ regulatory T lymphocytes through the induction of anergy and infectious tolerance. *J Immunol* 180:2830-2838.
55. Weber, S. E., J. Harbertson, E. Godebu, G. A. Mros, R. C. Padrick, B. D. Carson, S. F. Ziegler, and L. M. Bradley. 2006. Adaptive islet-specific regulatory CD4 T cells control autoimmune diabetes and mediate the disappearance of pathogenic Th1 cells in vivo. *J Immunol* 176:4730-4739.
56. Zhang, Q., F. Cui, L. Fang, J. Hong, B. Zheng, and J. Z. Zhang. TNF-alpha impairs differentiation and function of TGF-beta-induced Treg cells in autoimmune diseases through Akt and Smad3 signaling pathway. *J Mol Cell Biol* 5:85-98.
57. Brun, V., V. Neveu, Y. M. Pers, S. Fabre, B. Quatannens, H. Bastian, N. Clerget-Chossat, C. Jorgensen, and A. Foussat. 2011. Isolation of functional autologous collagen-II specific IL-10 producing Tr1 cell clones from rheumatoid arthritis blood. *Int Immunopharmacol* 11:1074-1078.
58. Floess, S., J. Freyer, C. Siewert, U. Baron, S. Olek, J. Polansky, K. Schlawe, H. D. Chang, T. Bopp, E. Schmitt, S. Klein-Hessling, E. Serfling, A. Hamann, and J. Huehn. 2007. Epigenetic control of the foxp3 locus in regulatory T cells. *PLoS Biol* 5:e38.
59. Polansky, J. K., K. Kretschmer, J. Freyer, S. Floess, A. Garbe, U. Baron, S. Olek, A. Hamann, H. von Boehmer, and J. Huehn. 2008. DNA methylation controls Foxp3 gene expression. *Eur J Immunol* 38:1654-1663.
60. Nadkarni, S., C. Mauri, and M. R. Ehrenstein. 2007. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. *J Exp Med* 204:33-39.

61. Stephens, G. L., J. Andersson, and E. M. Shevach. 2007. Distinct subsets of FoxP3+ regulatory T cells participate in the control of immune responses. *J Immunol* 178:6901-6911.
62. Apetoh, L., F. J. Quintana, C. Pot, N. Joller, S. Xiao, D. Kumar, E. J. Burns, D. H. Sherr, H. L. Weiner, and V. K. Kuchroo. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. *Nat Immunol* 11:854-861.
63. Hegazy, A. N., M. Peine, C. Helmstetter, I. Panse, A. Frohlich, A. Bergthaler, L. Flatz, D. D. Pinschewer, A. Radbruch, and M. Lohning. Interferons direct Th2 cell reprogramming to generate a stable GATA-3(+)T-bet(+) cell subset with combined Th2 and Th1 cell functions. *Immunity* 32:116-128.
64. Amodio, G., M. Comi, D. Tomasoni, M. E. Gianolini, R. Rizzo, J. LeMaout, M. G. Roncarolo, and S. Gregori. 2015. HLA-G expression levels influence the tolerogenic activity of human DC-10. *Haematologica*.
65. Suffia, I., S. K. Reckling, G. Salay, and Y. Belkaid. 2005. A role for CD103 in the retention of CD4+CD25+ Treg and control of Leishmania major infection. *J Immunol* 174:5444-5455.
66. Cepek, K. L., S. K. Shaw, C. M. Parker, G. J. Russell, J. S. Morrow, D. L. Rimm, and M. B. Brenner. 1994. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. *Nature* 372:190-193.
67. Hanazawa, A., K. Hayashizaki, K. Shinoda, H. Yagita, K. Okumura, M. Lohning, T. Hara, S. Tani-ichi, K. Ikuta, B. Eckes, A. Radbruch, K. Tokoyoda, and T. Nakayama. CD49b-dependent establishment of T helper cell memory. *Immunol Cell Biol* 91:524-531.

Figure and figure Legends






FIGURE 1. DC-induced CD49b⁺ cells display an effector memory phenotype. Percentage of naïve (CD44^{low}CD62L^{high}) and effector memory (CD44^{high}CD62L^{low}) T cells within the CD4, CD25 and CD49b gated populations (For gating strategy see

808 Fig S1A) were analyzed by flow cytometry for DC-injected (DC-Inj, n=10) and non-
809 injected mice (Non-Inj, n=3). A, Representative dot plots within gated CD4 (left),
810 CD25 (middle) and CD49b (right) positive cells in non-injected (top panels) and DC-
811 injected mice (bottom panels). B, Percentages of naïve and effector memory cells
812 within the gated CD4 (left), CD25 (middle) and CD49b (right) cell population. Each
813 symbol represents an individual mouse and bars show the mean \pm SEM. Data are
814 representative of two independent experiments. * $p < 0.05$, **** $p < 0.0001$ by repeated
815 measures two-way ANOVA (Bonferroni's multiple comparisons test).
816

A



B



818 **FIGURE 2.** Transcriptional profile of CD49b⁺ Treg cells contains multiple transcripts
819 of the canonical Treg signature. A, Venn diagram depicting the number of commonly
820 and uniquely down-regulated (left) or up-regulated (right) transcripts, in the FACS-
821 sorted CD49b⁺ and CD25⁺ Treg cell populations, with the canonical Treg signature.
822 B, Bar graphs show the transcriptional expression variation of the differentially
823 expressed genes common among the CD49b⁺, CD25⁺ and the canonical Treg
824 signature.
825

Figure 3




FIGURE 3. Several canonical markers of CD25⁺FoxP3⁺ Treg cells are expressed by CD49b⁺ effector memory cells. A, Representative flow cytometry analyses of splenocytes from DC-injected mice (n=18) within the gated CD4 (left), CD25 (middle) and CD49b (right) cell populations. Quadrants were set as indicated and frequencies

of cells are shown within each quadrant. Each symbol represents a pool of 2 mice and bars show the mean \pm SEM. **** $p<0.0001$, *** $p=0.0005$, ** $p=0.01$ and * $p=0.013$ by repeated measures two-way ANOVA (Tukey's multiple comparisons test).

B, The FACS-sorted CD4, CD25 and CD49b T cell populations from DC-vaccinated mice ($n=18$) were analyzed by FACS 48 hours following *in vitro* stimulation. Gates and quadrants were set as indicated and frequencies of cells are shown. Each symbol represents a pool of 6 mice and bars show the mean \pm SEM. **** $p<0.0001$, *** $p=0.0001$, ** $p=0.002$ and * $p=0.03$ by repeated measures two-way ANOVA (Tukey's multiple comparisons test).





FIGURE 4. Peripherally induced CD49b⁺ cells express Neuropilin-1 without co-expressing Helios. Representative flow cytometry analyses of splenocytes from DC-injected mice ($n=18$) within the gated CD4 (left), CD25 (middle) and CD49b (right) cell population. Quadrants were set as indicated and percentages of Helios, Nrp-1 or double positive cells were analyzed. Each symbol represents a pool of 2 mice and bars show the mean \pm SEM. **** $p<0.0001$ by repeated measures two-way ANOVA (Tukey's multiple comparisons test).



849

850 **FIGURE 5.** Peripherally induced CD49b⁺ cells express Th2-specific transcriptional
 851 factors and display a dominant Th2 cytokine profile. Percentages of cells expressing
 852 T-bet, Gata3 and transcriptional factors associated with IL-10 production, including c-
 853 Maf and AhR, were analyzed within the gated CD4, CD25 and CD49b cell
 854 populations from DC-injected splenocytes (n=18). A, Representative histogram plots
 855 of T-bet and Gata3 staining in gated CD4, CD25 and CD49b cell populations were

compared to *in vitro* polarized Th1 and Th2 cells. Percentages of Gata3⁺ and double positive Gata3⁺T-bet⁺ cells are represented with mean \pm SEM, each symbol representing a pool of 2 mice. Data are representative of two independent experiments. **** p<0.0001, *** p=0.0003 by repeated measures two-way ANOVA (Tukey's multiple comparisons test). B, Representative dot plots and percentages of AhR⁺ and c-Maf⁺ cells in gated CD4, CD25 and CD49b cell populations. Each symbol represents a pool of 2 mice and bars show the mean \pm SEM. Data are representative of two independent experiments. **** p<0.0001 by repeated measures one-way ANOVA (Tukey's multiple comparisons test). C, Level of cytokine secretion by highly purified cells following *in vitro* activation.




FIGURE 6. Polyclonal and Ag-specific CD49b⁺ T reg cells display potent *in vitro* and *in vivo* suppressive capacities. A, Comparable suppressive capacities of FACS-sorted CD25⁺ and CD49b⁺ Treg cells *in vitro*. CFSE-labeled effector T (Teff) cells

871 were cultured in activating conditions with titrated numbers of CD4⁺, CD25⁺ or
872 CD49b⁺ T cell population at different Treg/Teff ratios. As positive control for T cell
873 proliferation, Teff cells were cultured alone in activating conditions (ctrl). Results are
874 representative of three independent experiments. B, C, D, Comparison of the
875 suppressive function of Treg cells *in vivo* in the experimental model of CIA. Mice
876 were intravenously injected with 150,000 FACS-sorted T cells or with PBS on day 28
877 after immunization. Means of the severity scores of arthritis are represented for each
878 group with a maximal score of 40 per mouse. B, Comparison of the therapeutic
879 potential of polyclonal CD49b⁺ (CD49b) and CD25⁺ (CD25) Treg cells isolated from
880 syngeneic DBA/1 mice as well as Ag-specific CD49b⁺ cells (CD49b TBC) isolated
881 from TBC mice. Data are represented as mean \pm SEM of each group. C, Relative
882 arthritic scores were calculated for each independent experiment using the mean of
883 the PBS-treated mice (PBS, 5 independent experiments) as 100% disease severity.
884 Each symbol represents a mouse and bars represent the mean \pm SEM. Results
885 obtained with polyclonal CD49b⁺ (CD49b, 4 independent experiments), Ag-specific
886 CD49b⁺ (CD49bTBC, 2 independent experiments), and CD25⁺ (CD25, 4 independent
887 experiments) Treg cells as well as CD4⁺ T cells treated mice (CD4, 4 independent
888 experiments) are represented. * $p < 0.05$ by one-way ANOVA (Tukey's multiple
889 comparisons test). D, The suppressive mechanism of CD49b⁺ Treg cells is partially
890 dependent on IL-10. Therapeutic potential of CD49b⁺ Treg cells FACS-sorted from
891 IL-10 KO mice (CD49b IL-10 KO) or from wild-type littermates (CD49b), and CD25⁺
892 Treg cells FACS-sorted from wild-type littermates (CD25) were compared in CIA (n=7
893 to 9 mice per group). Data are represented as mean \pm SEM of each group, and are
894 representative of 2 independent experiments. * $p < 0.05$ by repeated measures two-
895 way ANOVA (Tukey's multiple comparisons test). Significant differences were

896 observed from days 50 to 59 for CD49b treated mice compared with PBS-injected
897 mice; and from day 59 for CD25 treated mice compared with PBS-injected mice.
898